US1570851014 - Common Stock
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cerus (NASDAQ:CERS) just reported results for the first quarter of 2024.Cerus r...
CERS stock results show that Cerus met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cerus (NASDAQ:CERS) just reported results for the fourth quarter of 2023.Cerus ...
CERS stock results show that Cerus beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
The widely followed growth investor keeps making moves.
Cantor Fitzgerald picks AVITA Medical (RCEL) as its best 2024 medtech idea, while remaining bullish on AXGN, CERS, ELUT, XGN, NNOX, NPCE, NYXH, SIBN, and PACB. Read more here.
These innovation-oriented companies could take flight this year.
Cerus Corporation reports 6% increase in fourth-quarter product revenue. Full-year unaudited revenue for 2023 expected to be $156.4 million.